Quantinno Capital Management LP Grows Position in Smith & Nephew SNATS, Inc. $SNN

Quantinno Capital Management LP grew its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 46.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 278,224 shares of the medical equipment provider’s stock after buying an additional 88,068 shares during the period. Quantinno Capital Management LP’s holdings in Smith & Nephew SNATS were worth $8,842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Garner Asset Management Corp purchased a new stake in Smith & Nephew SNATS during the fourth quarter worth $27,000. Arax Advisory Partners increased its holdings in Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 569 shares in the last quarter. Advisors Asset Management Inc. purchased a new position in Smith & Nephew SNATS in the fourth quarter valued at $36,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Smith & Nephew SNATS in the third quarter worth about $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Smith & Nephew SNATS during the 4th quarter worth about $43,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Stock Down 5.2%

Shares of Smith & Nephew SNATS stock opened at $30.48 on Wednesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57. The stock’s 50 day simple moving average is $30.45 and its 200-day simple moving average is $32.18. Smith & Nephew SNATS, Inc. has a 1-year low of $28.56 and a 1-year high of $38.79.

Analysts Set New Price Targets

A number of brokerages have issued reports on SNN. Kepler Capital Markets downgraded Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Thursday, June 4th. The Goldman Sachs Group reiterated a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. Canaccord Genuity Group reduced their price objective on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research report on Monday, May 11th. Weiss Ratings downgraded shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th. Finally, Sanford C. Bernstein set a $31.85 target price on shares of Smith & Nephew SNATS in a research note on Monday, May 11th. One investment analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Smith & Nephew SNATS has a consensus rating of “Hold” and a consensus price target of $30.93.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.